NCT07063849View on ClinicalTrials.gov

Pilot Influenza Challenge Study

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Influenza

Interventions

BIOLOGICAL

A/Texas

Live Influenza Virus RG-A/Texas/71/2017 H3N2 Dose: 1.0 mL (0.5mL per nostril) of approximately 1x10\^6 TCID50 Administered intranasally by atomizer device Challenge virus will be administered once on Day 1

Trial Locations (1)

63104

Saint Louis University Center for Vaccine Development, St Louis

All Listed Sponsors

lead

Daniel Hoft, MD, PhD

OTHER

NCT07063849 - Pilot Influenza Challenge Study | Biotech Hunter | Biotech Hunter